DETOUR System
Endologix, LLC · Decision date Jun 7, 2023
What did the FDA approve?
The FDA entry P220021 records an approval decision dated June 7, 2023, for the DETOUR System from Endologix, LLC, under product code QWM, device category "Stent graft, bypass, superficial femoral artery," specialty Cardiovascular, with decision status APPR. The statement describes the approved use as percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.
The record identifies this as an original approval rather than a supplement, so no prior PMA relationship is established by the identifier. The statement also excludes use in the coronary and cerebral vasculature. It reports the approved indication and its length and occlusion thresholds; it does not present trial data, adverse-event rates, or independent demonstration of safety or clinical effectiveness, and the supplied fields do not add such evidence.
FDA approval order statement
Approval for the DETOUR System for use for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis >70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments. The DETOUR System, or any of its components, is not for use in the coronary and cerebral vasculature.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 7, 2023
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220021
- Regulatory pathway
- Premarket approval application
- Applicant
- Endologix, LLC
- Product code
- QWM
- Decision code
- APPR
- Decision date
- Jun 7, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent graft, bypass, superficial femoral artery.
- Applicant
- Endologix, LLC
- Product code
- QWM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220021 received
Application receipt date recorded by FDA.
P220021 · FDA decision
APPR
P220021/S009 · Related supplement
DETOUR System
Timeline entries are records held by MedtechLedger for P220021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DETOUR SystemP220021/S009 | Endologix, LLC | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endologix, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3910 Brickway Blvd., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records